Repeated treatment of topical DNCB remarkably increased serum IgE production, whereas administration of cASCs and cASC-EVs reduced levels of serum IgE as a major characteristic of AD (Figure 2F and Table 1). This evidence concerns the gene IGHE and Alzheimer disease.